| scholarly article | Q13442814 |
| P2093 | author name string | D Rasnick | |
| P J Rosenthal | |||
| J T Palmer | |||
| W S Wollish | |||
| P2860 | cites work | 59 Inhibitors of lysosomal function | Q70309713 |
| Cathepsin B, Cathepsin H, and cathepsin L | Q28277583 | ||
| Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues | Q28323197 | ||
| Rational design of peptide-based HIV proteinase inhibitors | Q28330897 | ||
| Synthesis and properties of peptidyl derivatives of arginylfluoromethanes | Q28361238 | ||
| The synthesis of peptidylfluoromethanes and their properties as inhibitors of serine proteinases and cysteine proteinases | Q28362222 | ||
| Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability | Q29617252 | ||
| Biochemistry of Plasmodium (malarial parasites) | Q33624148 | ||
| Design of Specific Inhibitors of Angiotensin-Converting Enzyme: New Class of Orally Active Antihypertensive Agents | Q34936463 | ||
| A malarial cysteine proteinase is necessary for hemoglobin degradation by Plasmodium falciparum | Q35592776 | ||
| Identification of three stage-specific proteinases of Plasmodium falciparum | Q36353862 | ||
| The spread of chloroquine-resistant malaria in Africa. Implications for travelers | Q38653060 | ||
| Altered membrane transport of malaria-infected erythrocytes: a possible pharmacologic target | Q38694402 | ||
| Disease problems in the Third World | Q38776269 | ||
| Acid-vesicle function, intracellular pathogens, and the action of chloroquine against Plasmodium falciparum | Q39663518 | ||
| Intracellular proteases | Q39664942 | ||
| Malaria--resurgence, resistance, and research (second of two parts). | Q40146675 | ||
| Lack of Cross-Resistance to 4-Aminoquinolines in Chloroquine-Resistant Plasmodium falciparum In vitro | Q41921813 | ||
| Synthesis of peptide fluoromethyl ketones and the inhibition of human cathepsin B. | Q42229796 | ||
| Visualization of time-dependent inactivation of human tumor cathepsin B isozymes by a peptidyl fluoromethyl ketone using a fluorescent print technique | Q67946051 | ||
| Cysteine proteinase activity in arthritic rat knee joints and the effects of a selective systemic inhibitor, Z-Phe-AlaCH2F | Q67991328 | ||
| Inhibition of intraerythrocytic development of Plasmodium falciparum by proteinase inhibitors | Q68925338 | ||
| Plasmodium falciparum: inhibitors of lysosomal cysteine proteinases inhibit a trophozoite proteinase and block parasite development | Q69532002 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Plasmodium falciparum | Q311383 |
| antimalarial | Q521616 | ||
| P304 | page(s) | 1467-1472 | |
| P577 | publication date | 1991-11-01 | |
| P1433 | published in | Journal of Clinical Investigation | Q3186904 |
| P1476 | title | Antimalarial effects of peptide inhibitors of a Plasmodium falciparum cysteine proteinase | |
| P478 | volume | 88 |
| Q40001873 | 2-(3,4-dihydro-4-oxothieno[2,3-d]pyrimidin-2-ylthio) acetamides as a new class of falcipain-2 inhibitors. 3. design, synthesis and biological evaluation |
| Q46153985 | 2-amido-3-(1H-indol-3-yl)-N-substituted-propanamides as a new class of falcipain-2 inhibitors. 1. Design, synthesis, biological evaluation and binding model studies. |
| Q33526535 | A cell-based high-throughput screen validates the plasmodial surface anion channel as an antimalarial target |
| Q37335883 | A cysteine protease inhibitor rescues mice from a lethal Cryptosporidium parvum infection |
| Q71835192 | An initial characterization of the proteolytic enzymes secreted by the adult stage of the human hookwormNecator americanus |
| Q33586646 | An overview of chemotherapeutic targets for antimalarial drug discovery |
| Q41646262 | Analysis of non-peptidic compounds as potential malarial inhibitors against Plasmodial cysteine proteases via integrated virtual screening workflow |
| Q34231399 | Antimalarial activities of novel synthetic cysteine protease inhibitors |
| Q43208746 | Antimalarial activity of ultra-short peptides. |
| Q35541777 | Antimalarial drug discovery: old and new approaches |
| Q35125482 | Antimalarial effects of vinyl sulfone cysteine proteinase inhibitors |
| Q33696222 | Antimalarial synergy of cysteine and aspartic protease inhibitors |
| Q41438679 | BDA-410: a novel synthetic calpain inhibitor active against blood stage malaria |
| Q37635978 | Cathepsin proteases in Toxoplasma gondii |
| Q21032482 | Challenges of drug-resistant malaria |
| Q36744868 | Changes in the plasmodial surface anion channel reduce leupeptin uptake and can confer drug resistance in Plasmodium falciparum-infected erythrocytes. |
| Q58646654 | Characterization of a cysteine proteinase from Taenia crassiceps cysts |
| Q41745894 | Characterization of native and recombinant falcipain-2, a principal trophozoite cysteine protease and essential hemoglobinase of Plasmodium falciparum |
| Q73059919 | Characterization of native falcipain, an enzyme involved in Plasmodium falciparum hemoglobin degradation |
| Q30043603 | Characterization of the Plasmodium falciparum M17 leucyl aminopeptidase. A protease involved in amino acid regulation with potential for antimalarial drug development |
| Q33981743 | Comparison of efficacies of cysteine protease inhibitors against five strains of Plasmodium falciparum |
| Q31102747 | Critical role of amino acid 23 in mediating activity and specificity of vinckepain-2, a papain-family cysteine protease of rodent malaria parasites |
| Q33649956 | Cysteine protease inhibitors as chemotherapy for parasitic infections |
| Q39215179 | Design, Synthesis, and Biological Evaluation of Peptidomimetic N-Substituted Cbz-4-Hyp-Hpa-Amides as Novel Inhibitors of Plasmodium falciparum |
| Q40399170 | Discovery of novel antimalarial compounds enabled by QSAR-based virtual screening |
| Q35050387 | Emerging targets for antimalarial drugs |
| Q45062318 | Evaluation of cysteine proteases of Plasmodium vivax as antimalarial drug targets: sequence analysis and sensitivity to cysteine protease inhibitors |
| Q41649990 | Expression and alteration of the S2 subsite of the Leishmania major cathepsin B-like cysteine protease |
| Q27973740 | Expression and characterization of the Plasmodium falciparum haemoglobinase falcipain-3 |
| Q28484312 | Expression, characterization, and cellular localization of knowpains, papain-like cysteine proteases of the Plasmodium knowlesi malaria parasite |
| Q38066268 | Falcipain inhibitors as potential therapeutics for resistant strains of malaria: a patent review. |
| Q35415207 | Functional expression of falcipain, a Plasmodium falciparum cysteine proteinase, supports its role as a malarial hemoglobinase. |
| Q37357541 | Gene disruption confirms a critical role for the cysteine protease falcipain-2 in hemoglobin hydrolysis by Plasmodium falciparum |
| Q48037131 | Generation of hemoglobin peptides in the acidic digestive vacuole of Plasmodium falciparum implicates peptide transport in amino acid production |
| Q34415972 | Hemoglobin catabolism and iron utilization by malaria parasites |
| Q33428555 | Hemoglobin cleavage site-specificity of the Plasmodium falciparum cysteine proteases falcipain-2 and falcipain-3. |
| Q42156927 | Identification and biochemical characterization of vivapains, cysteine proteases of the malaria parasite Plasmodium vivax |
| Q30042132 | Identification and characterization of falcilysin, a metallopeptidase involved in hemoglobin catabolism within the malaria parasite Plasmodium falciparum |
| Q48036921 | Identification of hemoglobin degradation products in Plasmodium falciparum |
| Q39472582 | In vitro activity of riboflavin against the human malaria parasite Plasmodium falciparum |
| Q44660942 | Independent intramolecular mediators of folding, activity, and inhibition for the Plasmodium falciparum cysteine protease falcipain-2. |
| Q33893538 | Inhibition of a Plasmodium vinckei cysteine proteinase cures murine malaria |
| Q54125170 | Inhibition of trypanosomal cysteine proteinases by their propeptides. |
| Q36181679 | Intracellular structures of normal and aberrant Plasmodium falciparum malaria parasites imaged by soft x-ray microscopy |
| Q44377251 | Killing of intraerythrocytic Plasmodium falciparum by lysosomotropic amino acid esters |
| Q30538078 | Malaria parasites tolerate a broad range of ionic environments and do not require host cation remodelling |
| Q34350086 | Molecular characterization and inhibition of a Plasmodium falciparum aspartic hemoglobinase. |
| Q42732002 | Multi-targeted activity of maslinic acid as an antimalarial natural compound |
| Q36579600 | Non-canonical maturation of two papain-family proteases in Toxoplasma gondii |
| Q35026098 | Novel anti-plasmodial hits identified by virtual screening of the ZINC database |
| Q35112789 | Novel antiplasmodial agents |
| Q34139669 | Order and specificity of the Plasmodium falciparum hemoglobin degradation pathway |
| Q44472936 | Plasmodium falciparum falcilysin: an unprocessed food vacuole enzyme |
| Q36559835 | Probing the structure of falcipain-3, a cysteine protease from Plasmodium falciparum: comparative protein modeling and docking studies |
| Q37064248 | Proteases of malaria parasites: new targets for chemotherapy |
| Q31081478 | Resistance of Entamoeba histolytica to the cysteine proteinase inhibitor E64 is associated with secretion of pro-enzymes and reduced pathogenicity |
| Q41913918 | Selection of cysteine protease inhibitor-resistant malaria parasites is accompanied by amplification of falcipain genes and alteration in inhibitor transport |
| Q44511093 | Selective inhibition of a two-step egress of malaria parasites from the host erythrocyte |
| Q30890602 | Solid-phase library synthesis of reversed-statine type inhibitors of the malarial aspartyl proteases plasmepsin I and II. |
| Q38344740 | Soluble expression of a functionally active Plasmodium falciparum falcipain-2 fused to maltose-binding protein in Escherichia coli |
| Q44056198 | Stage-specific antimalarial activity of cysteine protease inhibitors |
| Q48031305 | Structural and functional characterization of Falcipain-2, a hemoglobinase from the malarial parasite Plasmodium falciparum |
| Q28914748 | Structural basis for unique mechanisms of folding and hemoglobin binding by a malarial protease |
| Q44858731 | Structural characterization of vivapain-2 and vivapain-3, cysteine proteases from Plasmodium vivax: comparative protein modeling and docking studies |
| Q24597864 | Structure and inhibition of plasmepsin II, a hemoglobin-degrading enzyme from Plasmodium falciparum |
| Q43245922 | Substrate mapping and inhibitor profiling of falcipain-2, falcipain-3 and berghepain-2: implications for peptidase anti-malarial drug discovery |
| Q44935373 | Synthesis and antiplasmodial activity of a cysteine protease-inhibiting biotinylated aziridine-2,3-dicarboxylate |
| Q33878982 | The Plasmodium falciparum cysteine protease falcipain-2 captures its substrate, hemoglobin, via a unique motif |
| Q35663448 | The cysteine proteinase inhibitor Z-Phe-Ala-CHN2 alters cell morphology and cell division activity of Trypanosoma brucei bloodstream forms in vivo |
| Q27645777 | X-ray structural analysis of Plasmodium falciparum enoyl acyl carrier protein reductase as a pathway toward the optimization of triclosan antimalarial efficacy |
Search more.